EUVIMEDEUVIMED entdecken
Crossref

SN‐38, an active metabolite of irinotecan, inhibits transcription of nuclear factor erythroid 2‐related factor 2 and enhances drug sensitivity of colorectal cancer cells

Jingya Wang, Jiangli Xu, Shuhui Yang, Liu He, Wenhuai Xu, Yan'e Liu, Baoshan Cao, Siwang Yu

Molecular Carcinogenesis · 2024

DOI: 10.1002/mc.23685 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2024. Verfasst von Jingya Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Natural and Biomimetic Drugs, Department of Molecular and Cellular Pharmacology, Peking University School of Pharmaceutical S…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Colorectal Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nuclear factor erythroid 2‐related factor 2 (Nrf2) significantly contributes to drug resistance of cancer cells, and Nrf2 inhibitors have been vigorously pursued. Repurposing of existing drugs, especially anticancer drugs, is a straightforward and promising strategy to find clinically available Nrf2 inhibitors and effective drug combinations. Topoisomerase inhibitors SN‐38 (an active metabolite of irinotecan), topotecan, mitoxantrone, and epirubicin were found to significantly suppress Nrf2 transcriptional activity in cancer cells. SN‐38, the most potent one among them, significantly inhibited the transcription of Nrf2, as indicated by decreased mRNA level and binding of RNA polymerase II to NFE2L2 gene, while no impact on Nrf2 protein or mRNA degradation was observed. SN‐38 synergized with Nrf2‐sensitive anticancer drugs such as mitomycin C in killing colorectal cancer cells, and irinotecan and mitomycin C synergistically inhibited the growth of SW480 xenografts in nude mice. Our study identified SN‐38 and three other topoisomerase inhibitors as Nrf2 inhibitors, revealed the Nrf2‐inhibitory mechanism of SN‐38, and indicate that clinically feasible drug combinations could be designed based on their interactions with Nrf2 signaling.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsColorectal NeoplasmsAnimalsMiceHumansIrinotecanCamptothecinMitomycinMice, NudeNF-E2-Related Factor 2Drug Resistance, NeoplasmTopoisomerase InhibitorsDrug Combinations

Stichwörter der Autor:innen

Nrf2 inhibitorchemo-sensitizationcolorectal canceririnotecantopoisomerase inhibitor

Substanzen

IrinotecanCamptothecinMitomycinNF-E2-Related Factor 2Antineoplastic AgentsTopoisomerase InhibitorsDrug Combinations

Autor:innen und Institutionen

  • State Key Laboratory of Natural and Biomimetic Drugs, Department of Molecular and Cellular Pharmacology, Peking University School of Pharmaceutical Sciences, Beijing, P.R. China.
  • Key Laboratory of State Administration of Traditional Chinese Medicine for Compatibility Toxicology, Peking University Health Science Center, Beijing, P.R. China.
  • Department of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wang, J., Xu, J., Yang, S., He, L., Xu, W., Liu, Y., Cao, B., & Yu, S. (2024). SN‐38, an active metabolite of irinotecan, inhibits transcription of nuclear factor erythroid 2‐related factor 2 and enhances drug sensitivity of colorectal cancer cells. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23685

Vancouver

Wang J, Xu J, Yang S, He L, Xu W, Liu Y, et al. SN‐38, an active metabolite of irinotecan, inhibits transcription of nuclear factor erythroid 2‐related factor 2 and enhances drug sensitivity of colorectal cancer cells. Molecular Carcinogenesis. 2024. doi:10.1002/mc.23685

BibTeX
@article{Wang2024,
  author = {Wang, Jingya and Xu, Jiangli and Yang, Shuhui and He, Liu and Xu, Wenhuai and Liu, Yan'e and Cao, Baoshan and Yu, Siwang},
  title = {SN‐38, an active metabolite of irinotecan, inhibits transcription of nuclear factor erythroid 2‐related factor 2 and enhances drug sensitivity of colorectal cancer cells},
  journal = {Molecular Carcinogenesis},
  year = {2024},
  doi = {10.1002/mc.23685}
}
Kostenlos starten →